Developer docs
API playgroundTry for free, no card

Search company profiles

ENYO Pharma

Full company profile

uuid0000nec

Namestring
ENYO Pharma
Legal namestring
ENYO Pharma SA
Websiteurl
enyopharma.com
Company typeenum
Private
Founded yearint
2014
Descriptiontext

ENYO Pharma is a clinical-stage biopharmaceutical company founded in 2014 and headquartered in Lyon, France. The company develops FXR (Farnesoid X Receptor) agonist therapeutics targeting rare genetic kidney diseases, with a primary focus on Alport Syndrome, alongside broader chronic kidney disease (CKD) and diabetic kidney disease (DKD). ENYO serves patients with impaired kidney function, particularly the rare Alport Syndrome population (approximately 1 in 5,000 to 10,000 births globally), where no approved disease-modifying treatments currently exist. The company's lead asset Vonafexor (EYP001) received Orphan Drug Designation from both the FDA and EMA for Alport Syndrome in 2023.

The company's core technology is a virus-inspired drug discovery platform that identifies novel cellular targets and develops first-in-class drug candidates. Vonafexor is a once-daily, oral, non-bile acid FXR agonist with a unique chemical scaffold engineered to prioritize delivery to the kidney, regulating metabolic, inflammatory, and fibrotic pathways central to renal injury and extracellular matrix remodeling. The pipeline includes EYP651, a next-generation FXR agonist entering Phase 2 in H2 2026 for common renal diseases, and EYP002 (MITO-C), a preclinical program targeting NEET proteins for metabolic and neurodegenerative diseases. ENYO has accumulated clinical data from 9 completed Phase I/II studies covering 400+ subjects. In January 2026, the Phase 2 ALPESTRIA-1 trial demonstrated reversal of kidney function decline in Alport Syndrome patients (eGFR slope shift from -6.4 to +4.8 mL/min/1.73 m²/yr), with 73% of patients maintaining albuminuria reduction three months off-drug.

ENYO is a privately-held, pre-revenue clinical-stage biopharmaceutical company that has raised over €101 million cumulatively across Series A (€22M in 2016, led by Sofinnova Partners), Series B (€40M in 2018, co-led by OrbiMed and Morningside Ventures), and Series C (€39M announced January 2024, with final closing at €32M in June 2025). Its investor base includes OrbiMed, Morningside Ventures, Sofinnova Partners, Bpifrance (InnoBio and Large Venture), Andera Partners, and Vesalius Biocapital IV. The go-to-market approach relies on direct engagement with nephrologists and specialized kidney disease centers through clinical trial sites in France, the USA, Spain, Germany, and Australia, with future distribution to target nephrology specialists through standard pharmaceutical channels upon regulatory approval.

Short descriptiontext

ENYO Pharma is a clinical-stage biopharmaceutical company developing FXR agonist therapeutics for rare and chronic kidney diseases, with lead asset Vonafexor in Phase 2/3 for Alport Syndrome and CKD/DKD. The company serves patients with impaired kidney function, particularly rare disease populations with no approved disease-modifying treatments.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersLyon, France
HQ citystring
Lyon
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
kidney disease therapeutics, FXR agonist drugs, clinical-stage biopharmaceuticals, rare renal disease treatment, nephrology drug development
Industry2 codes
PRIMARYHLAIAIAI
Rare Renal & Nephrology Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIACAH
Nephrology & Urology Specialty Pharmaceuticals
NAICS code1 code
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Nephrology Therapeutics
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Drug Development and Commercialization
TypeOne Time License
Description

ENYO Pharma is a clinical-stage biopharmaceutical company without approved products. The company develops proprietary drug candidates (Vonafexor, EYP651) targeting kidney diseases. Revenue will be generated through pharmaceutical product sales upon regulatory approval.

enyopharma.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

ENYO Pharma is a clinical-stage biopharmaceutical company developing proprietary small-molecule FXR (Farnesoid X Receptor) agonists for kidney and liver diseases. Its lead clinical compound, Vonafexor (EYP001), is a once-daily oral non-bile acid FXR agonist in Phase 2 development for Alport Syndrome and Chronic Kidney Disease (CKD), with the pipeline extending to next-generation FXR agonist EYP651 and preclinical NEET protein program EYP002 (MITO-C).

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Vonafexor reversed historical mean eGFR decline of -6.4 mL/min/1.73 m²/yr to +4.8 mL/min/1.73 m²/yr functional gain in Alport Syndrome patients
+2 more records
Product overview1 text field

ENYO Pharma is a clinical-stage biopharmaceutical company developing a focused pipeline of FXR agonist therapeutics for kidney diseases. The company's core product is Vonafexor (EYP001), a first-in-class oral FXR agonist currently in Phase 2 development for Alport Syndrome and chronic kidney diseases. The pipeline also includes EYP651, a next-generation FXR agonist entering Phase 2 for common renal diseases (CKD/DKD), and EYP002 (MITO-C), a preclinical program targeting NEET proteins for potential applications in metabolic and neurodegenerative diseases. The company leverages a virus-inspired drug discovery platform to identify novel therapeutic candidates.

Product and service3 records
1Vonafexor (EYP001)
CategoryClinical-stage small molecule therapeutic (FXR agonist)
Description

Once-daily, oral, non-bile acid FXR agonist with a renal-tropic chemical scaffold designed to prioritize kidney delivery. Targets metabolic, inflammatory, and fibrotic pathways involved in renal injury and extracellular matrix remodeling. In Phase 2 development for Alport Syndrome and CKD, with prior Phase 2a activity in chronic hepatitis B (LIVIFY) and NASH. Holds Orphan Drug Designation from FDA and EMA for Alport Syndrome.

2EYP651
CategoryClinical-stage small molecule therapeutic (FXR agonist)
Description

Next-generation FXR agonist being advanced into Phase 2 clinical studies in the second half of 2026 for common renal diseases, including chronic kidney disease (CKD) and diabetic kidney disease (DKD). Designed to expand the kidney franchise beyond the rare disease setting.

3EYP002 (MITO-C)
CategoryPreclinical small molecule program
Description

Preclinical program of small molecules in the MITO-C class that target the NEET family of proteins involved in mitochondrial morphodynamics and ER-mitochondria contact sites. Explored for therapeutic applications in metabolic and neurodegenerative diseases beyond the original infectious-disease focus.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership11 partners
Strategic tierSupportingTypeStrategic or Co-development PartnerAnnounced on2017-12-13
Description

Research collaboration with Prof. Julian Walters to evaluate therapeutic potential of FXR agonist EYP001 using human ileum explants.

2Paris Diderot University
Strategic tierSupportingTypeStrategic or Co-development PartnerAnnounced on2017-10-18
Description

Collaboration with Institut Universitaire d'Hématologie to discover new drugs against adenoviruses using ENYO's virus-inspired approach.

enyopharma.com
Strategic tierSupportingTypeOthersAnnounced on2017-07-26
Description

First international subsidiary established in Australia as clinical trial management hub for Asia-Pacific region.

Strategic tierSupportingTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2015-05-06
Description

License agreement granting ENYO access to POXEL's FXR agonist compounds for therapeutic indications in infectiology, with POXEL retaining rights for cardiovascular and metabolic indications.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2015-01-01
Description

Collaboration with Dr. Fabiola Terzi's team at Inserm Unit U1151, Necker Children's Hospital, Paris, focusing on mechanisms and therapeutic strategies for chronic kidney diseases.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaboration with Dr. David Durantel's team at Inserm U1111 studying Hepatitis B and D virus interactions with hepatocytes and hepatic microenvironment.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaboration with Prof. Patrice André (co-founder) at Inserm U1111, Lyon, studying FXR agonist inhibition of HBV replication cycle.

8Swiss Institute of Bioinformatics
Strategic tierSupportingTypeStrategic or Co-development Partner
Description

Collaboration with CALIPHO group (Lydie Lane and Amos Bairoch) to integrate ENYO's protein interactome data into neXtProt platform for human protein research.

enyopharma.com
Strategic tierSupportingTypeStrategic or Co-development Partner
Description

Collaboration with Prof. Rachel Nechushtai on NEET protein modulators in various indications including oncology and diabetes.

Strategic tierSupportingTypeTechnology or Integration
Description

Technology partnership using Charles River's capture compound mass spectrometry for ENYO's target identification platform.

Strategic tierSupportingTypeStrategic or Co-development Partner
Description

Collaboration on in silico disease modeling for liver disease and PK/PD analysis for EYP001 in HBV patients.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Madrigal commercializes Resmetirom (Rezdiffra), the first FDA-approved treatment for MASH/NASH. Both companies have historical FXR/liver disease roots and pursued orphan-to-broader market strategies.

TypeDirect peer
Description

Intercept developed obeticholic acid (Ocaliva), a first-in-class FXR agonist approved for primary biliary cholangitis and historically pursued for NASH. It is the most direct comparator to ENYO's Vonafexor given shared FXR agonist mechanism and liver/kidney therapeutic ambitions.

TypeDirect peer
Description

Calliditas developed Nefecon (Tarpeyo), the first FDA-approved treatment for IgA nephropathy, a rare kidney disease. Like ENYO, Calliditas targets rare renal indications with high unmet need and pursued orphan drug pathways.

TypeDirect peer
Description

Travere commercializes Filspari (sparsentan) for IgA nephropathy and has pursued FSGS, focusing on rare kidney disease therapeutics with disease-modifying potential. Highly comparable commercial-stage rare renal disease peer to ENYO.

TypeDirect peer
Description

Vera is developing atacicept for IgA nephropathy and other rare autoimmune kidney diseases. As a clinical-to-commercial stage rare renal disease biotech, Vera shares ENYO's target patient population and regulatory pathway approach.

TypeDirect peer
Description

Chinook developed rare kidney disease therapies (zigakibart for IgA nephropathy, atrasentan for rare proteinuric kidney diseases) before being acquired by Novartis for $3.5B in 2023. Represents a successful exit trajectory for ENYO's rare renal disease focus.

TypeDirect peer
Description

Reata developed bardoxolone methyl (Skyclarys) for Friedreich's ataxia and explored CKD applications before Biogen acquired the company for $7.3B in 2023. Comparable rare disease biotech with kidney-focused clinical pipeline.

TypeBroad incumbent
Description

Otsuka markets tolvaptan (Jynarque) for ADPKD, the only FDA-approved therapy specifically for a rare polycystic kidney disease. Relevant comparable for ENYO's ADPKD expansion plans and as a benchmark for rare renal disease commercialization.

TypeDirect peer
Description

Galapagos has developed FXR agonist candidates (e.g., filgotinib-adjacent programs and earlier FXR work) and pivoted focus toward specialty/rare disease. European biotech peer with overlapping FXR and inflammatory disease expertise.

TypeBroad incumbent
Description

Gilead has developed multiple FXR agonists (cilofexor, tropifexor) and maintains significant liver disease infrastructure from its HBV/HCV franchise. As a broad incumbent, Gilead represents both a potential competitor and a likely partner/acquirer for late-stage ENYO assets.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles12 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors12 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

ENYO Pharma

Nephrology Therapeuticsenyopharma.com

ENYO Pharma is a clinical-stage biopharmaceutical company developing FXR agonist therapeutics for rare and chronic kidney diseases, with lead asset Vonafexor in Phase 2/3 for Alport Syndrome and CKD/DKD. The company serves patients with impaired kidney function, particularly rare disease populations with no approved disease-modifying treatments.

What ENYO Pharma does

ENYO Pharma is a clinical-stage biopharmaceutical company founded in 2014 and headquartered in Lyon, France. The company develops FXR (Farnesoid X Receptor) agonist therapeutics targeting rare genetic kidney diseases, with a primary focus on Alport Syndrome, alongside broader chronic kidney disease (CKD) and diabetic kidney disease (DKD). ENYO serves patients with impaired kidney function, particularly the rare Alport Syndrome population (approximately 1 in 5,000 to 10,000 births globally), where no approved disease-modifying treatments currently exist. The company's lead asset Vonafexor (EYP001) received Orphan Drug Designation from both the FDA and EMA for Alport Syndrome in 2023.

The company's core technology is a virus-inspired drug discovery platform that identifies novel cellular targets and develops first-in-class drug candidates. Vonafexor is a once-daily, oral, non-bile acid FXR agonist with a unique chemical scaffold engineered to prioritize delivery to the kidney, regulating metabolic, inflammatory, and fibrotic pathways central to renal injury and extracellular matrix remodeling. The pipeline includes EYP651, a next-generation FXR agonist entering Phase 2 in H2 2026 for common renal diseases, and EYP002 (MITO-C), a preclinical program targeting NEET proteins for metabolic and neurodegenerative diseases. ENYO has accumulated clinical data from 9 completed Phase I/II studies covering 400+ subjects. In January 2026, the Phase 2 ALPESTRIA-1 trial demonstrated reversal of kidney function decline in Alport Syndrome patients (eGFR slope shift from -6.4 to +4.8 mL/min/1.73 m²/yr), with 73% of patients maintaining albuminuria reduction three months off-drug.

ENYO is a privately-held, pre-revenue clinical-stage biopharmaceutical company that has raised over €101 million cumulatively across Series A (€22M in 2016, led by Sofinnova Partners), Series B (€40M in 2018, co-led by OrbiMed and Morningside Ventures), and Series C (€39M announced January 2024, with final closing at €32M in June 2025). Its investor base includes OrbiMed, Morningside Ventures, Sofinnova Partners, Bpifrance (InnoBio and Large Venture), Andera Partners, and Vesalius Biocapital IV. The go-to-market approach relies on direct engagement with nephrologists and specialized kidney disease centers through clinical trial sites in France, the USA, Spain, Germany, and Australia, with future distribution to target nephrology specialists through standard pharmaceutical channels upon regulatory approval.

ENYO Pharma firmographics

Firmographics
Name
ENYO Pharma
Legal name
ENYO Pharma SA
Website
https://enyopharma.com
Company type
Private
Founded year
2014
Operating status
Operating
Headcount range
11–50 employees
Short description
ENYO Pharma is a clinical-stage biopharmaceutical company developing FXR agonist therapeutics for rare and chronic kidney diseases, with lead asset Vonafexor in Phase 2/3 for Alport Syndrome and CKD/DKD. The company serves patients with impaired kidney function, particularly rare disease populations with no approved disease-modifying treatments.
Ownership category
akta.pro rank

ENYO Pharma industry classification

Industry
Product category
Nephrology Therapeutics
NAICS
Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAIAI
Rare Renal & Nephrology Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIACAH
Nephrology & Urology Specialty Pharmaceuticals

Keywords

  • Kidney disease therapeutics
  • FXR agonist drugs
  • Clinical-stage biopharmaceuticals
  • Rare renal disease treatment
  • Nephrology drug development

Where ENYO Pharma is headquartered

Location

Headquarters

HQ city
Lyon
HQ country
France
HQ region
Europe

Offices2 records

Markets served

ENYO Pharma business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

  1. Pharmaceutical Drug Development and Commercialization: ENYO Pharma is a clinical-stage biopharmaceutical company without approved products. The company develops proprietary drug candidates (Vonafexor, EYP651) targeting kidney diseases. Revenue will be generated through pharmaceutical product sales upon regulatory approval.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

ENYO Pharma product offering

Product offering

Core offering

ENYO Pharma is a clinical-stage biopharmaceutical company developing proprietary small-molecule FXR (Farnesoid X Receptor) agonists for kidney and liver diseases. Its lead clinical compound, Vonafexor (EYP001), is a once-daily oral non-bile acid FXR agonist in Phase 2 development for Alport Syndrome and Chronic Kidney Disease (CKD), with the pipeline extending to next-generation FXR agonist EYP651 and preclinical NEET protein program EYP002 (MITO-C).

Product overview

ENYO Pharma is a clinical-stage biopharmaceutical company developing a focused pipeline of FXR agonist therapeutics for kidney diseases. The company's core product is Vonafexor (EYP001), a first-in-class oral FXR agonist currently in Phase 2 development for Alport Syndrome and chronic kidney diseases. The pipeline also includes EYP651, a next-generation FXR agonist entering Phase 2 for common renal diseases (CKD/DKD), and EYP002 (MITO-C), a preclinical program targeting NEET proteins for potential applications in metabolic and neurodegenerative diseases. The company leverages a virus-inspired drug discovery platform to identify novel therapeutic candidates.

Differentiator

Problem solved

Functional benefit

Products and services

  • Vonafexor (EYP001) Once-daily, oral, non-bile acid FXR agonist with a renal-tropic chemical scaffold designed to prioritize kidney delivery. Targets metabolic, inflammatory, and fibrotic pathways involved in renal injury and extracellular matrix remodeling. In Phase 2 development for Alport Syndrome and CKD, with prior Phase 2a activity in chronic hepatitis B (LIVIFY) and NASH. Holds Orphan Drug Designation from FDA and EMA for Alport Syndrome.
  • EYP651 Next-generation FXR agonist being advanced into Phase 2 clinical studies in the second half of 2026 for common renal diseases, including chronic kidney disease (CKD) and diabetic kidney disease (DKD). Designed to expand the kidney franchise beyond the rare disease setting.
  • EYP002 (MITO-C) Preclinical program of small molecules in the MITO-C class that target the NEET family of proteins involved in mitochondrial morphodynamics and ER-mitochondria contact sites. Explored for therapeutic applications in metabolic and neurodegenerative diseases beyond the original infectious-disease focus.

Quantifiable outcome

  • Vonafexor reversed historical mean eGFR decline of -6.4 mL/min/1.73 m²/yr to +4.8 mL/min/1.73 m²/yr functional gain in Alport Syndrome patients
  • +2 more outcomes

Companies that use ENYO Pharma

Customer profile

Named customers1 record

Segments2 records

Ideal customer profiles2 records

ENYO Pharma technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

ENYO Pharma partnerships and signals

Strategic signal

Partnerships

Eleven partnerships are on record, tiered supporting and core.

  • Imperial College LondonsupportingStrategic or Co-development Partner · 13 December 2017Research collaboration with Prof. Julian Walters to evaluate therapeutic potential of FXR agonist EYP001 using human ileum explants.
  • Paris Diderot UniversitysupportingStrategic or Co-development Partner · 18 October 2017Collaboration with Institut Universitaire d'Hématologie to discover new drugs against adenoviruses using ENYO's virus-inspired approach.
  • Australia SubsidiarysupportingOthers · 26 July 2017First international subsidiary established in Australia as clinical trial management hub for Asia-Pacific region.
  • POXELsupportingOEM/ Whitelabel/ Licensing Partner · 6 May 2015License agreement granting ENYO access to POXEL's FXR agonist compounds for therapeutic indications in infectiology, with POXEL retaining rights for cardiovascular and metabolic indications.
  • Inserm (Dr. Fabiola Terzi)coreStrategic or Co-development Partner · 1 January 2015Collaboration with Dr. Fabiola Terzi's team at Inserm Unit U1151, Necker Children's Hospital, Paris, focusing on mechanisms and therapeutic strategies for chronic kidney diseases.
  • Inserm (Dr. David Durantel)coreStrategic or Co-development PartnerCollaboration with Dr. David Durantel's team at Inserm U1111 studying Hepatitis B and D virus interactions with hepatocytes and hepatic microenvironment.
  • Inserm (Prof. Patrice André)coreStrategic or Co-development PartnerCollaboration with Prof. Patrice André (co-founder) at Inserm U1111, Lyon, studying FXR agonist inhibition of HBV replication cycle.
  • Swiss Institute of BioinformaticssupportingStrategic or Co-development PartnerCollaboration with CALIPHO group (Lydie Lane and Amos Bairoch) to integrate ENYO's protein interactome data into neXtProt platform for human protein research.
  • Hebrew University of JerusalemsupportingStrategic or Co-development PartnerCollaboration with Prof. Rachel Nechushtai on NEET protein modulators in various indications including oncology and diabetes.
  • Charles River LaboratoriessupportingTechnology or IntegrationTechnology partnership using Charles River's capture compound mass spectrometry for ENYO's target identification platform.
  • NovadiscoverysupportingStrategic or Co-development PartnerCollaboration on in silico disease modeling for liver disease and PK/PD analysis for EYP001 in HBV patients.

Scale indicators6 records

Recent moves7 records

Expansion highlights6 records

ENYO Pharma competitors and assessment

Company assessment

Broad incumbents

  • Madrigal Pharmaceuticals: Madrigal commercializes Resmetirom (Rezdiffra), the first FDA-approved treatment for MASH/NASH. Both companies have historical FXR/liver disease roots and pursued orphan-to-broader market strategies.
  • Otsuka Pharmaceutical: Otsuka markets tolvaptan (Jynarque) for ADPKD, the only FDA-approved therapy specifically for a rare polycystic kidney disease. Relevant comparable for ENYO's ADPKD expansion plans and as a benchmark for rare renal disease commercialization.
  • Gilead Sciences: Gilead has developed multiple FXR agonists (cilofexor, tropifexor) and maintains significant liver disease infrastructure from its HBV/HCV franchise. As a broad incumbent, Gilead represents both a potential competitor and a likely partner/acquirer for late-stage ENYO assets.

Direct peers

  • Intercept Pharmaceuticals: Intercept developed obeticholic acid (Ocaliva), a first-in-class FXR agonist approved for primary biliary cholangitis and historically pursued for NASH. It is the most direct comparator to ENYO's Vonafexor given shared FXR agonist mechanism and liver/kidney therapeutic ambitions.
  • Calliditas Therapeutics: Calliditas developed Nefecon (Tarpeyo), the first FDA-approved treatment for IgA nephropathy, a rare kidney disease. Like ENYO, Calliditas targets rare renal indications with high unmet need and pursued orphan drug pathways.
  • Travere Therapeutics: Travere commercializes Filspari (sparsentan) for IgA nephropathy and has pursued FSGS, focusing on rare kidney disease therapeutics with disease-modifying potential. Highly comparable commercial-stage rare renal disease peer to ENYO.
  • Vera Therapeutics: Vera is developing atacicept for IgA nephropathy and other rare autoimmune kidney diseases. As a clinical-to-commercial stage rare renal disease biotech, Vera shares ENYO's target patient population and regulatory pathway approach.
  • Chinook Therapeutics (Novartis): Chinook developed rare kidney disease therapies (zigakibart for IgA nephropathy, atrasentan for rare proteinuric kidney diseases) before being acquired by Novartis for $3.5B in 2023. Represents a successful exit trajectory for ENYO's rare renal disease focus.
  • Reata Pharmaceuticals (Biogen): Reata developed bardoxolone methyl (Skyclarys) for Friedreich's ataxia and explored CKD applications before Biogen acquired the company for $7.3B in 2023. Comparable rare disease biotech with kidney-focused clinical pipeline.
  • Galapagos NV: Galapagos has developed FXR agonist candidates (e.g., filgotinib-adjacent programs and earlier FXR work) and pivoted focus toward specialty/rare disease. European biotech peer with overlapping FXR and inflammatory disease expertise.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

ENYO Pharma social profiles

Digital presence

ENYO Pharma compliance and trust

Trust signal

Compliance1 record

ENYO Pharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

ENYO Pharma leadership team

Management profile

Number of profiles

Profiles12 records

ENYO Pharma subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

ENYO Pharma funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors12 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

ENYO Pharma M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ENYO Pharma

What does ENYO Pharma do?

ENYO Pharma is a clinical-stage biopharmaceutical company developing proprietary small-molecule FXR (Farnesoid X Receptor) agonists for kidney and liver diseases. Its lead clinical compound, Vonafexor (EYP001), is a once-daily oral non-bile acid FXR agonist in Phase 2 development for Alport Syndrome and Chronic Kidney Disease (CKD), with the pipeline extending to next-generation FXR agonist EYP651 and preclinical NEET protein program EYP002 (MITO-C).

Is ENYO Pharma a public or private company?

ENYO Pharma is a private company. It is classified as venture growth investor backed and is currently operating.

When was ENYO Pharma founded?

ENYO Pharma was founded in 2014. It employs 11 to 50 people.

Where is ENYO Pharma based?

ENYO Pharma is headquartered in Lyon, France, in the Europe region.

How does ENYO Pharma make money?

One revenue line is on record: pharmaceutical Drug Development and Commercialization.

Who are ENYO Pharma's main competitors?

Broad incumbents on record are Madrigal Pharmaceuticals, Otsuka Pharmaceutical and Gilead Sciences. Direct peers are Intercept Pharmaceuticals, Calliditas Therapeutics, Travere Therapeutics, Vera Therapeutics, Chinook Therapeutics (Novartis), Reata Pharmaceuticals (Biogen) and Galapagos NV.

Does ENYO Pharma have an API?

No public API is recorded for ENYO Pharma.

What industry is ENYO Pharma in?

ENYO Pharma's product category is Nephrology Therapeutics. Its primary akta.pro industry code is HLAIAIAI, Rare Renal & Nephrology Disorder Therapies, with a secondary code of HLAIACAH, Nephrology & Urology Specialty Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
TechBullion5 HealthTech Startups Developing Hepatology SolutionsThis article profiles five healthtech startups developing solutions for liver disease, a condition affecting hundreds of millions globally that often goes undiagnosed until advanced stages. The companies profiled—Akero Therapeutics, Madrigal Pharmaceuticals, Alentis Therapeutics, Enyo Pharma, and Pandorum Technologies—each take distinct approaches including drug development for MASH and Hepatitis B, antibody therapies for fibrosis and liver cancer, and bioengineered liver tissue. Madrigal Pharmaceuticals achieved a landmark in 2024 when the FDA approved Rezdiffra as the first treatment for MASH with liver fibrosis, while collectively these companies have raised over $1.4 billion, signaling significant investor interest in the hepatology space.HrtodayENYO Pharma Appoints Jeff George as Chairman to Support Next Phase of GrowthENYO Pharma, a clinical-stage biotechnology company based in Lyon, France, has appointed Jeff George as Chairman to support its next phase of growth and advance its clinical development programs in kidney disease therapeutics. George brings over two decades of global healthcare leadership experience, including previous roles as CEO of Alcon and Sandoz at Novartis, and currently serves as Managing Partner at healthcare-focused investment firm Maytal Capital. The appointment is expected to strengthen the company's strategic direction as it advances Vonafexor, its lead therapeutic compound, through Phase 2 clinical trials targeting chronic and rare kidney diseases.Business Wire BlogENYO Pharma Appoints Jeff George as Chairman to Support Next Phase of Growth and Phase 3 ReadinessENYO Pharma, a clinical-stage biotechnology company based in Lyon, France, has appointed Jeff George as Non-Executive Chairman of its Board of Directors to support governance and strategic capabilities ahead of Phase 3 development. The appointment coincides with preparations for a pivotal Phase 3 program of Vonafexor in Alport Syndrome, following positive Phase 2 clinical results and ahead of planned End-of-Phase 2 meetings with the U.S. FDA and EMA in Q3 2026. Jeff George brings extensive pharmaceutical leadership experience, including prior roles as global CEO of Sandoz and Alcon at Novartis and as Managing Partner of Maytal Capital.BarchartAlport Syndrome Market Trends, Innovation, and Future Growth Outlook to 2036 – DelveInsight | Eloxx Pharmac, Biogen, River 3 Renal Corp, Travere Therapeutics, Chinook TherapeuticsDelveInsight published a market insights report on Alport Syndrome, a rare genetic kidney disorder, estimating the market at USD 20 million in 2025 with projected growth at a 39% CAGR through 2036. In December 2025, Bayer launched a Phase IIa clinical trial for its investigational monoclonal antibody BAY 3401016 targeting kidney damage progression in Alport Syndrome patients. Separately, ENYO Pharma announced successful progression of its Phase 2 ALPESTRIA-1 trial in June 2025 and completed a Series C funding round raising EUR 32 million.BioSpaceENYO Pharma Announces Completion of Series C Financing With Vesalius Biocapital and Continued Progress of Its ALPESTRIA-1 Clinical Phase 2 Study in Alport Syndrome PatientsENYO Pharma completed a €32 million Series C financing, including a €6 million investment from Vesalius Biocapital IV. The funds will support two new clinical programs and expand preclinical research, while the ALPESTRIA-1 Phase 2 trial in Alport syndrome patients continues with topline results expected in Q4 2025.Business Wire IndiaENYO Pharma Announces a €39 Million Series C Financing and FDA Clearance to Advance Vonafexor in a Phase 2 Clinical Trial for Patients With Alport SyndromeENYO Pharma has received FDA clearance to initiate a Phase 2 clinical trial of Vonafexor for Alport Syndrome, set to begin in the first half of 2024. The company also announced the first closing of a €39 million Series C financing, which will support this trial and further research and development through 2026. This represents a significant milestone for ENYO as it looks to address unmet needs in kidney disease treatment.EnyopharmaENYO Pharma announces a €39 million Series C financing and FDA clearance to advance Vonafexor in a Phase 2 clinical trial for patients with Alport syndrome – ENYO PharmaENYO Pharma has received FDA clearance to initiate a Phase 2 clinical study of Vonafexor for treating Alport syndrome, with the study named ALPESTRIA-1 to begin in the first half of 2024. The company also announced the closing of a €39 million Series C financing round to support this study and further research and development through the first half of 2026. This clearance marks a significant milestone for ENYO as it aims to address unmet needs in renal disease treatments.BioSpaceENYO Pharma Announces a €39 Million Series C Financing and FDA Clearance to Advance Vonafexor in a Phase 2 Clinical Trial for Patients With Alport SyndromeEnyo Pharma announced the receipt of FDA clearance for its Investigational New Drug application to initiate a Phase 2 clinical study of Vonafexor for Alport Syndrome, alongside the first closing of a €39 million Series C financing. The funding, co-led by OrbiMed and Morningside Ventures, will support the ALPESTRIA-1 study and further research into other kidney diseases through early 2026. This development marks a significant milestone as Enyo advances its lead candidate in renal disease treatment.Business Wire BlogENYO Pharma Announces a €39 Million Series C Financing and FDA Clearance to Advance Vonafexor in a Phase 2 Clinical Trial for Patients With Alport SyndromeENYO Pharma secured a €39 million Series C financing and received FDA clearance to initiate a Phase 2 clinical trial for Vonafexor in treating Alport Syndrome. The funding, co-led by OrbiMed and Morningside Ventures, will support the upcoming ALPESTRIA-1 study and further research into other kidney diseases through the first half of 2026.GlobalgenesEnyo Raises $42.5 Million to Advance Development of Experimental Alport Syndrome TherapyEnyo Pharma secured a $42.5 million Series C financing and received FDA clearance to initiate a Phase 2 clinical study for its experimental therapy Vonafexor targeting Alport Syndrome. The funding, co-led by OrbiMed and Morningside Ventures, will support the Alpestria-1 trial and further research into other kidney diseases such as ADPKD.